BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22486070)

  • 1. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.
    Jensen PS
    Am J Manag Care; 2009 May; 15(5 Suppl):S129-40. PubMed ID: 19601688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD.
    Isaksson J; Hogmark Å; Nilsson KW; Lindblad F
    Psychiatry Res; 2013 Oct; 209(3):740-1. PubMed ID: 23850434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.
    Hodgkins P; Sasané R; Meijer WM
    Clin Ther; 2011 Feb; 33(2):188-203. PubMed ID: 21497704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Better health care for children and adolescents with attention deficit hyperactivity disorder].
    Klasen H; Verhulst FC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1723-5. PubMed ID: 16114286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.